Post by TherapeutAix

The evolving IPF landscape: new opportunities, familiar challenges. After years of frustration in idiopathic pulmonary fibrosis (IPF) development, the FDA approval of nerandomilast offers fresh momentum. Yet this milestone also raises strategic questions: how will combinations with nintedanib or pirfenidone be managed, and what does this mean for the next wave of antifibrotics? In our latest blog, we explore how this approval reshapes therapeutic positioning and what developers should consider when designing the next generation of anti-fibrotic treatments. 🔗 https://lnkd.in/eBggsNPW #IPF #DrugDevelopment #Fibrosis #TranslationalScience #TherapeutAix